The Fentanyl Inflection Point: How Synthetic Opioids Transformed the ER Overdose Crisis

The opioid epidemic did not begin with fentanyl. It began in the late 1990s, when pharmaceutical companies — most notoriously Purdue Pharma — aggressively marketed extended-release oxycodone to physicians with misleading claims about its addiction potential. By 2010, prescription opioid overdose deaths had quadrupled from their 1999 baseline. But the epidemic's deadliest chapter began in 2013, when illicitly manufactured fentanyl began appearing in the heroin supply — and accelerated dramatically in 2016, when it became the dominant driver of overdose deaths in America.

Three Waves: Understanding the Opioid Epidemic's Progression

The CDC has characterized the opioid epidemic as occurring in three distinct waves, each driven by a different drug class. The first wave, beginning in the late 1990s, was driven by prescription opioids — oxycodone, hydrocodone, and methadone. Overdose deaths from prescription opioids rose steadily through the 2000s, peaking at approximately 17,000 deaths per year in 2010.

The second wave began around 2010, when heroin use surged among people who had become dependent on prescription opioids. As prescription opioid supplies tightened following the FDA's reformulation of OxyContin in 2010 and increased prescribing scrutiny, many people with opioid use disorder transitioned to heroin, which was cheaper and more readily available. Heroin overdose deaths more than tripled between 2010 and 2015.

The third wave — the fentanyl wave — began in 2013 and became dominant by 2016. Illicitly manufactured fentanyl, produced primarily in clandestine laboratories in China and Mexico and trafficked through the same distribution networks as heroin, began appearing in the heroin supply as an adulterant. By 2016, the CDC reported that synthetic opioids (primarily illicitly manufactured fentanyl) had surpassed both prescription opioids and heroin as the leading cause of opioid overdose deaths. In 2017, synthetic opioids were involved in 59% of all opioid overdose deaths — 28,466 deaths in a single year.

What Fentanyl Did to the Emergency Department

Emergency physicians who had been managing opioid overdoses for years described the fentanyl era as qualitatively different from anything that had come before. The drug's extreme potency — 50 to 100 times that of morphine, and 25 to 50 times that of heroin — meant that overdoses were faster, more severe, and more likely to be fatal before emergency services could respond.

The standard treatment for opioid overdose — naloxone (Narcan) — remained effective against fentanyl, but the doses required were often higher than those used for heroin overdoses, and the duration of naloxone's effect (30 to 90 minutes) was sometimes shorter than fentanyl's effect, leading to re-narcotization after apparent recovery. Emergency physicians began routinely administering multiple doses of naloxone and extending observation periods for suspected fentanyl overdoses.

The volume of overdose presentations to emergency departments increased dramatically. Between 2015 and 2017, ER visits for opioid overdoses increased by 30% nationally, according to the Agency for Healthcare Research and Quality. In states with the highest fentanyl burden — Ohio, West Virginia, Pennsylvania, and Massachusetts — the increases were far greater. Some emergency departments in hard-hit communities reported that overdose presentations accounted for 10 to 15% of their total volume during peak periods.

Purdue Pharma and the Origins of the Crisis

The fentanyl crisis did not emerge in a vacuum. It was the downstream consequence of a decade of aggressive opioid marketing that flooded American communities with prescription opioids and created the conditions for widespread opioid use disorder. Purdue Pharma's role in that process has been extensively documented through litigation, congressional investigations, and the company's own internal documents.

OxyContin, Purdue's extended-release oxycodone formulation, was approved by the FDA in 1995 and marketed with the claim that its extended-release mechanism made it less addictive than immediate-release opioids — a claim that was not supported by clinical evidence and that Purdue's own internal documents showed the company knew to be misleading. Purdue's sales force was trained to minimize concerns about addiction and to target high-prescribing physicians with gifts, speaking fees, and continuing medical education programs that promoted opioid prescribing.

In 2007, Purdue Pharma and three of its executives pleaded guilty to federal charges of misbranding OxyContin and paid $634 million in fines — at the time, one of the largest criminal fines ever imposed on a pharmaceutical company. The settlement did not stop the marketing practices or the prescribing surge. By 2012, enough opioid prescriptions were written in the United States to give every American adult a bottle of pills.

Purdue Pharma filed for bankruptcy in 2019 as part of a settlement of thousands of lawsuits brought by states, counties, and cities. The Sackler family, which owned Purdue, agreed to pay approximately $4.5 billion as part of the settlement — a figure that critics noted was a fraction of the estimated $13 billion the family had extracted from the company during the opioid epidemic. The settlement was contested for years in the courts, with the Supreme Court ultimately ruling in 2024 on the scope of the liability protections available to the Sackler family.

The ER Response: Naloxone, Buprenorphine, and Harm Reduction

Emergency medicine's response to the opioid crisis evolved significantly over the decade from 2013 to 2023. The initial response focused on naloxone distribution — expanding access to the overdose reversal medication through standing orders, community distribution programs, and co-prescription with opioid prescriptions. By 2016, most states had enacted laws allowing pharmacists to dispense naloxone without a prescription, and many emergency departments had begun distributing naloxone kits to overdose patients and their families before discharge.

A more significant shift came with the growing evidence base for buprenorphine initiation in the emergency department. A landmark 2015 study published in JAMA by Dr. Gail D'Onofrio and colleagues at Yale demonstrated that patients with opioid use disorder who were started on buprenorphine in the emergency department were significantly more likely to be engaged in addiction treatment 30 days later compared to those who received only brief intervention or referral. The study catalyzed a movement to make emergency departments a point of entry into medication-assisted treatment for opioid use disorder.

By 2020, emergency department-initiated buprenorphine had become an evidence-based standard of care, endorsed by ACEP, SAEM, and the Substance Abuse and Mental Health Services Administration. The 2026 CDC opioid prescribing guidelines explicitly endorse buprenorphine initiation in the emergency department as a recommended practice for patients presenting with opioid use disorder.

The Crisis in 2026: Fentanyl Analogues and Xylazine

The opioid crisis has continued to evolve since the fentanyl inflection point of 2016. Illicitly manufactured fentanyl analogues — including carfentanil, which is approximately 100 times more potent than fentanyl itself — have appeared in the drug supply in various regions. More recently, xylazine, a veterinary sedative with no approved human use, has been detected in a growing proportion of fentanyl samples in the eastern United States. Xylazine is not an opioid and is not reversed by naloxone, creating a new clinical challenge for emergency physicians managing overdoses in which the drug is present.

In 2023, the DEA reported that xylazine was detected in fentanyl samples in 48 of 50 states. The combination of fentanyl and xylazine — sometimes called "tranq dope" — produces a deeper, more prolonged sedation than fentanyl alone and is associated with severe skin wounds and necrosis at injection sites that present to emergency departments as complex wound care challenges. The 2026 CDC opioid guidelines address xylazine for the first time, recommending that emergency physicians administer naloxone for all suspected opioid overdoses even when xylazine is suspected, as fentanyl is almost always co-present.

The total U.S. drug overdose death toll reached 107,622 in 2021, the highest ever recorded. Preliminary data for 2025 suggest the number has declined modestly — to approximately 94,000 — following expanded naloxone access, increased buprenorphine prescribing, and fentanyl test strip distribution programs. Emergency medicine has been central to that modest progress, and central to the ongoing crisis.

The Numbers: A Decade of the Opioid Crisis